Biopharma | January 11, 2026
InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Harbour BioMed brings advanced antibody discovery platforms to the table
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Subscribe To Our Newsletter & Stay Updated
